Business Wire

Adtran Networks SE reports second quarter 2023 results

8.8.2023 06:00:00 EEST | Business Wire | Press release

Share

Adtran Networks SE (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported financial results for the second quarter 2023 ended on June 30, 2023. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).

Q2 2023 financial summary1

(in thousands of EUR)

Q2

Q2

Change

Q1

Change

 

 

2023

2022

 

2023

 

 

 

 

Revenues

170,188

166,320

2.3%

179,358

-5.1%

 

Pro forma gross profit

60,232

54,336

10.9%

58,371

3.2%

 

in % of revenues

35.4%

32.7%

2.7pp

32.5%

2.8pp

 

Pro forma EBIT

12,092

6,435

87.9%

9,730

24.3%

 

in % of revenues

7.1%

3.9%

3.2pp

5.4%

1.7pp

 

Operating income2

8,033

4,655

72.6%

6,227

29.0%

 

Net income

3,288

7,291

-54.9%

3,627

-9.3%

 

 

 

(in thousands of EUR)

Jun. 30

2023

Jun. 30

2022

Change

Mar. 31

2023

Change

 

Cash and cash equivalents

48,595

63,187

-23,1%

67,241

-27.7%

 

Net cash (+) / Net debt (-)3

-33,457

-946

-3,436.7%

-24,296

-37.7%

 

1 Potential difference due to rounding

2 Q2 2023 including EUR 1.7 million, Q1 2023 including EUR 1.6 million and Q2 2022 including EUR 0.4 million extraordinary expenses

3 Q2 2023 including EUR 53.0 million and Q1 2023 Including EUR 62.0 million financial liabilities to Adtran Holdings, Inc.

Q2 2023 IFRS financial results
Revenue in Q2 2023 was down 5.1% to EUR 170.2 million from EUR 179.4 million in Q1 2023 and was up 2.3% compared to EUR 166.3 million in Q2 2022. The US Dollar depreciation negatively impacted both year-over-year and quarter-over-quarter revenue. The decrease compared to the previous quarter was mainly due to a softening in demand compared to a strong Q1 2023.

Pro forma gross profit in Q2 2023 was up 3.2% to EUR 60.2 million (35.4% of revenues) from EUR 58.4 million (32.5% of revenues) in Q1 2023 and increased by 10.9% from EUR 54.3 million (32.7% of revenues) in the year-ago quarter. The margin increase is due to lower procurement costs related to the recovery of supply bottlenecks and the US Dollar depreciation.

Pro forma EBIT in Q2 2023 was EUR 12.1 million (7.1% of revenues), up 24.3% from EUR 9.7 million (5.4% of revenues) in Q1 2023. Compared to the year-ago quarter, pro forma operating income increased by 87.9% from EUR 6.4 million (3.9% of revenues). The increase in pro forma EBIT is mainly due to the improvement in gross margin.

Operating income increased by 29.0% from EUR 6.2 million in Q1 2023 to EUR 8.0 million in Q2 2023 and increased by 72.6% compared to EUR 4.7 million in Q2 2022.

Net income was EUR 3.3 million in Q2 2023, down 9.3% compared to EUR 3.6 million in Q1 2023 and down 54.9% compared to EUR 7.3 million in Q2 2022. The decrease in net income was due to higher tax charges in Q2 2023.

The company’s cash and cash equivalents decreased by EUR 18.6 million to EUR 48.6 million compared to EUR 67.2 million at the end of Q1 2023 and decreased by EUR 14.6m million compared to EUR 63.2 million in Q2 2022.

The company’s net debt increased by EUR 9.2 million from EUR 24.3 million in Q1 2023 to EUR 33.5 million in Q2 2023 and increased by EUR 32.5 million compared to EUR 0.9 million in Q2 2022.

Management commentary
“Our Q2 2023 results were in line with our expectations. We anticipate the second half of 2023 will continue to present challenges due to customers optimizing inventory and the macro-economic environment,” said Tom Stanton, CEO of Adtran Networks SE. “Nevertheless, we continue to believe that we are in the early stage of an unprecedented investment cycle and Adtran Networks is well positioned to be one of the largest beneficiaries.”

The company will publish its financial results for Q3 2023 on November 7, 2023.

The complete half-year report 2023 (January – June) is available as a PDF: https://www.adva.com/en/about-us/investors/financial-results/financial-statements

Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of Adtran Networks. Adtran Networks is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of Adtran Networks or the market in the shares of Adtran Networks.

Use of pro forma financial information
Adtran Networks SE provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of Adtran Networks operating results from one financial period to another. Adtran Networks believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, non-recurring expenses relating to M&A restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.

About Adtran Networks SE
Adtran Networks SE is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by
Adtran Networks SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press
Gareth Spence
+44 1904 699 358
public-relations@adva.com

For investors
Steven Williams
+49 89 890 665 918
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye